Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy
Brian Warnecke,1 Misako Nagasaka1,2 1Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, Department o...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/adagrasib-in-the-treatment-of-kras-pg12c-positive-advanced-nsclc-desig-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846140180864434176 |
|---|---|
| author | Warnecke B Nagasaka M |
| author_facet | Warnecke B Nagasaka M |
| author_sort | Warnecke B |
| collection | DOAJ |
| description | Brian Warnecke,1 Misako Nagasaka1,2 1Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA, Email nagasakm@hs.uci.eduAbstract: One of the most common mutations seen in lung cancers are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS), observed in 25– 30% of patients with NSCLC. Mutations in KRAS result in oncogenesis via persistent activation of the MAPK/ERK pathways. Although once thought to be “undruggable”, KRAS p.G12C inhibitors such as sotorasib and adagrasib have been developed. This paper focuses on adagrasib, the second KRAS p.G12C inhibitor to obtain regulatory approval by the FDA and describes the details on its study design, development and current place in therapy.Keywords: Kristen Rat Sarcoma Viral Oncogene Homolog, sotorasib, AMG510, MRTX849, KRYSTAL, CodeBreaK, brain penetration |
| format | Article |
| id | doaj-art-0efa164d82a54a04a5e3ddc403c610dd |
| institution | Kabale University |
| issn | 1177-8881 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj-art-0efa164d82a54a04a5e3ddc403c610dd2024-12-05T16:54:29ZengDove Medical PressDrug Design, Development and Therapy1177-88812024-12-01Volume 185673568397983Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in TherapyWarnecke BNagasaka MBrian Warnecke,1 Misako Nagasaka1,2 1Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA, Email nagasakm@hs.uci.eduAbstract: One of the most common mutations seen in lung cancers are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS), observed in 25– 30% of patients with NSCLC. Mutations in KRAS result in oncogenesis via persistent activation of the MAPK/ERK pathways. Although once thought to be “undruggable”, KRAS p.G12C inhibitors such as sotorasib and adagrasib have been developed. This paper focuses on adagrasib, the second KRAS p.G12C inhibitor to obtain regulatory approval by the FDA and describes the details on its study design, development and current place in therapy.Keywords: Kristen Rat Sarcoma Viral Oncogene Homolog, sotorasib, AMG510, MRTX849, KRYSTAL, CodeBreaK, brain penetrationhttps://www.dovepress.com/adagrasib-in-the-treatment-of-kras-pg12c-positive-advanced-nsclc-desig-peer-reviewed-fulltext-article-DDDTkristen rat sarcoma viral oncogene homologsotorasibamg510mrtx849krystalcodebreakbrain penetration |
| spellingShingle | Warnecke B Nagasaka M Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy Drug Design, Development and Therapy kristen rat sarcoma viral oncogene homolog sotorasib amg510 mrtx849 krystal codebreak brain penetration |
| title | Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy |
| title_full | Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy |
| title_fullStr | Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy |
| title_full_unstemmed | Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy |
| title_short | Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy |
| title_sort | adagrasib in the treatment of kras p g12c positive advanced nsclc design development and place in therapy |
| topic | kristen rat sarcoma viral oncogene homolog sotorasib amg510 mrtx849 krystal codebreak brain penetration |
| url | https://www.dovepress.com/adagrasib-in-the-treatment-of-kras-pg12c-positive-advanced-nsclc-desig-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT warneckeb adagrasibinthetreatmentofkraspg12cpositiveadvancednsclcdesigndevelopmentandplaceintherapy AT nagasakam adagrasibinthetreatmentofkraspg12cpositiveadvancednsclcdesigndevelopmentandplaceintherapy |